Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $88.94 -17.27%
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.18, $0.03 better than the analyst estimate of $0.15. Revenue for the quarter came in at $66.8 million versus the consensus estimate of $69.61 million.
GUIDANCE:
Corcept Therapeutics sees FY2019 revenue of $285-315 million, versus the consensus of $298.3 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
